Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion
Judah Frommer

Judah Frommer Analyst Performance

Senior Equity Research Analyst, SMid Cap Biotech at Morgan Stanley

Judah Frommer is a stock analyst at Morgan Stanley across a range of sectors, covering 26 publicly traded companies. Over the past year, Judah Frommer has issued 24 stock ratings, including buy and hold recommendations. While full access to Judah Frommer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Judah Frommer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
84 Last 8 Years
Buy Recommendations
63.10% 53 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy63.1%53 ratings
Hold34.5%29 ratings
Sell2.4%2 ratings

Out of 84 total stock ratings issued by Judah Frommer at Morgan Stanley, the majority (63.1%) have been Buy recommendations, followed by 34.5% Hold and 2.4% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
76.9% of companies on NASDAQ
20 companies
NYSE
23.1% of companies on NYSE
6 companies

Judah Frommer, an analyst at Morgan Stanley, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
15 companies
57.7%
Retail/Wholesale
5 companies
19.2%
Consumer Staples
4 companies
15.4%
Manufacturing
2 companies
7.7%

Judah Frommer of Morgan Stanley specializes in stock coverage within the Medical sector, with additional focus on Retail/Wholesale and Consumer Staples companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
13 companies
50.0%
CONS PD - MISC STPL
2 companies
7.7%
RETAIL - DISCOUNT
2 companies
7.7%
FOOD - MISC/DIVERSIFIED
2 companies
7.7%
Miscellaneous
1 company
3.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
3.8%
MED - DRUGS
1 company
3.8%
MED - OUTP/HM CRE
1 company
3.8%
RETAIL - MISC/DIV
1 company
3.8%
RETAIL - SUPERMKT
1 company
3.8%
FOOD ITEMS - WHLE
1 company
3.8%

Judah Frommer's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
5/14/2026Boost Price Target$19.11$22.00Equal Weight
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
5/12/2026Boost Price Target$22.57$37.00Overweight
Evommune, Inc. stock logo
EVMN
Evommune
5/11/2026Boost Price Target$24.54$55.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
5/6/2026Reiterated Rating$14.66$20.00Overweight
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
4/16/2026Initiated Coverage$5.87$14.00Overweight
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3/25/2026Initiated Coverage$8.57$20.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3/18/2026Lower Price Target$10.80$18.00Overweight
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3/17/2026Boost Price Target$23.23$21.00Equal Weight
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/5/2026Lower Price Target$8.72$17.00Overweight
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
3/3/2026Initiated Coverage$16.21$28.00Overweight
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
3/3/2026Boost Price Target$173.12$201.00Overweight
Evommune, Inc. stock logo
EVMN
Evommune
2/18/2026Reiterated Rating$31.12$54.00Overweight
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2/16/2026Initiated Coverage$30.03$34.00Equal Weight
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2/10/2026Lower Price Target$8.92$18.00Overweight
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
1/9/2026Boost Price Target$115.49$145.00Overweight
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1/6/2026Initiated Coverage$159.42$191.00Overweight
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1/5/2026Downgrade$13.62$19.00Equal Weight
Evommune, Inc. stock logo
EVMN
Evommune
12/1/2025Initiated Coverage$20.71$36.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
11/14/2025Boost Price Target$11.46$19.00Overweight
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
11/13/2025Boost Price Target$35.80$37.00Overweight
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9/12/2025Boost Price Target$83.12$101.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
8/21/2025Initiated Coverage$7.42$18.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
7/2/2025Boost Price Target$18.25$26.00Equal Weight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/5/2025Boost Price Target$127.99$129.00Equal Weight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5/9/2025Lower Price Target$18.79$43.00Overweight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3/20/2025Initiated Coverage$19.95$46.00Overweight
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3/20/2025Reiterated Rating$6.84$12.00Equal Weight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
3/20/2025Initiated Coverage$90.53$100.00Equal Weight
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/14/2025Boost Price Target$6.55$24.00Overweight
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
2/14/2025Downgrade$25.49$22.00Underweight
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
1/13/2025Lower Price Target$4.80$6.00Underweight